Results

1–3 of 3 results for biosimilar

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Biosimilars: What Can Retina Learn from Oncology?
Kathy W Oubre, MS
Updates from the Field
2022
New Biosimilar Bevacizumab and Ranibizumab for Retinal Diseases
Alay S. Banker, MD
Annual Meeting Talks
2018